News

TB R&D Weekly Update: Podcast interview on TB Drug Tolerance and Efflux Pumps

Photos of Lalita Ramakrishnan, Paul Edelstein, and Christine Cosma

Listen to Lalita Ramakrishnan Podcast


Summary: The WGND had the opportunity to interview three researchers (Lalita Ramakrishnan, Paul Edelstein, and Christine Cosma) involved in the groundbreaking research on the role of efflux pumps in contributing to drug tolerance during TB treatment which was published in the April 1 issue of Cell. The article is entitled “Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism.” Dr. Ramakrishnan is Professor in the Department of Microbiology, at the University of Washington. Dr. Edelstein is Director of the Clinical Microbiology Laboratory at the University of Pennsylvania. Dr. Cosma is a Research Scientist at the University of Washington. In the interview, we discuss the background of each guest interviewee, key results presented in the article, and next steps for clinical testing of compounds that inhibit efflux pumps and experiments for learning more about this mechanism for inducing drug tolerance.

Additional TB R&D News:

Critical Path Institute Announces Expansion of Regulatory Science Consortium for Tuberculosis

Sequella Licenses Rights to Commercialize SQ109 for Tuberculosis in Russia to Maxwell Biotech Venture Fund Subsidiary

The arsenal to fight microbes is very weak right now

TB diagnostics: all studies recruiting patients now

Registering New Drugs for Low-Income Countries: The African Challenge

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...